Ford SJ - Search Results

1

Luminal iron levels govern intestinal tumorigenesis after Apc loss in vivo.

Radulescu S, Brookes MJ, Salgueiro P, Ridgway RA, McGhee E, Anderson K, Ford SJ, Stones DH, Iqbal TH, Tselepis C, Sansom OJ. Radulescu S, et al. Among authors: ford sj. Cell Rep. 2012 Aug 30;2(2):270-82. doi: 10.1016/j.celrep.2012.07.003. Epub 2012 Aug 9. Cell Rep. 2012. PMID: 22884366 Free article.

2

Luminal Iron Levels Govern Intestinal Tumorigenesis after Apc Loss In Vivo.

Radulescu S, Brookes MJ, Salgueiro P, Ridgway RA, McGhee E, Anderson K, Ford SJ, Stones DH, Iqbal TH, Tselepis C, Sansom OJ. Radulescu S, et al. Among authors: ford sj. Cell Rep. 2016 Dec 6;17(10):2805-2807. doi: 10.1016/j.celrep.2016.10.028. Cell Rep. 2016. PMID: 27926880 Free article. No abstract available.

3

Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.

Ford SJ, Obeidy P, Lovejoy DB, Bedford M, Nichols L, Chadwick C, Tucker O, Lui GY, Kalinowski DS, Jansson PJ, Iqbal TH, Alderson D, Richardson DR, Tselepis C. Ford SJ, et al. Br J Pharmacol. 2013 Mar;168(6):1316-28. doi: 10.1111/bph.12045. Br J Pharmacol. 2013. PMID: 23126308 Free PMC article.

4

Iron chelation in the treatment of cancer: a new role for deferasirox?

Bedford MR, Ford SJ, Horniblow RD, Iqbal TH, Tselepis C. Bedford MR, et al. Among authors: ford sj. J Clin Pharmacol. 2013 Sep;53(9):885-91. doi: 10.1002/jcph.113. Epub 2013 Jun 6. J Clin Pharmacol. 2013. PMID: 23740857 Review.

5

A comparative study of the iron status of patients with oesophageal adenocarcinoma to determine suitability for a clinical trial of iron chelation therapy.

Ford SJ, Bedford MR, Pang W, Wood A, Iqbal T, Tselepis C, Tucker O. Ford SJ, et al. Ann R Coll Surg Engl. 2014 May;96(4):275-8. doi: 10.1308/003588414X13946184900282. Ann R Coll Surg Engl. 2014. PMID: 24780018 Free PMC article.

6

Characterization of the transition-metal-binding properties of hepcidin.

Tselepis C, Ford SJ, McKie AT, Vogel W, Zoller H, Simpson RJ, Diaz Castro J, Iqbal TH, Ward DG. Tselepis C, et al. Among authors: ford sj. Biochem J. 2010 Mar 29;427(2):289-96. doi: 10.1042/BJ20091521. Biochem J. 2010. PMID: 20113314

7

The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.

Lui GY, Obeidy P, Ford SJ, Tselepis C, Sharp DM, Jansson PJ, Kalinowski DS, Kovacevic Z, Lovejoy DB, Richardson DR. Lui GY, et al. Among authors: ford sj. Mol Pharmacol. 2013 Jan;83(1):179-90. doi: 10.1124/mol.112.081893. Epub 2012 Oct 16. Mol Pharmacol. 2013. PMID: 23074173

8

Current patterns of care and outcomes for dermatofibrosarcoma protuberans: An international multi-institutional collaborative.

Winer LK, Akumuo R, Fredette JD, Deng M, Hasler JS, Greco SH, von Mehren M, Bartholomew AJ, Blazer DG, Gabrielova L, Adamkova D, Bernard-Bedard E, Nessim C, Kollár A, Olariu R, Cencelj-Arnez R, Hompes D, Ford SJ, Cardona K, Sato K, Iwata S, Farma JM, Villano AM. Winer LK, et al. Among authors: ford sj. Cancer. 2025 Jan 1;131(1):e35468. doi: 10.1002/cncr.35468. Epub 2024 Jul 10. Cancer. 2025. PMID: 38985726

9

Archives and amazons: A quilters guide to the lesbian archive.

Ford SJ. Ford SJ. J Lesbian Stud. 2024;28(2):321-342. doi: 10.1080/10894160.2024.2313381. Epub 2024 Feb 14. J Lesbian Stud. 2024. PMID: 38356159

10

Postoperative Complications After Retroperitoneal Sarcoma Surgery: Can We Avoid Them?

Tirotta F, Ford SJ. Tirotta F, et al. Among authors: ford sj. Ann Surg Oncol. 2023 Nov;30(12):6970-6971. doi: 10.1245/s10434-023-13704-z. Epub 2023 Aug 3. Ann Surg Oncol. 2023. PMID: 37535268 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

94 results

Search Page

Filters